Every material Form 8-K 10x Genomics, Inc. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
10x Genomics reported third-quarter 2026 revenue of $150.7 million, up 1% from a year earlier, with gross margin rising to 75% from 67% and the net loss narrowing to $19.4 million from $27.5 million. The company raised its full-year 2026 revenue guidance to $625 million to $635 million and began global commercial shipments of its Atera platform. Nine-month revenue was $452.5 million, down from $476.8 million a year earlier, as 2025 included larger patent settlement license revenue.
Q3 2026 revenue was $150.7 million, up 1% from $149.0 million in Q3 2025.
Gross margin was 75% versus 67%, and the net loss was $19.4 million versus $27.5 million.
2026 revenue guidance was raised to $625 million to $635 million from $610 million to $630 million.
Cash and marketable securities totaled $575.7 million as of September 30, 2026.
10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors effective immediately, with terms running to the 2028 annual meeting. Gilliam was also named Audit Committee chair on October 30, 2026, adding a senior financial and public-company governance voice to the board.
Board appointments made October 28, 2026 as Class III directors; terms expire at the 2028 annual meeting
Gilliam is President and COO of Glaukos Corporation and previously was its CFO; he was named Audit Committee chair on October 30, 2026
Each new director receives a $60,000 annual cash retainer, a one-time RSU grant with a $400,000 target value, and an annual RSU grant with a $215,000 target value
Satpathy previously served as a scientific advisor to the company under an agreement that was terminated in October 2026
10x Genomics reported second quarter 2026 revenue of $151.0 million, down from $172.9 million a year earlier, and a net loss of $17.9 million, compared with net income of $34.5 million in the prior-year quarter. The prior-year period included $27.3 million of patent settlement revenue, and excluding settlement revenue in both periods, revenue rose 3%. The company raised its full-year 2026 revenue guidance to $610 million to $630 million, which shareholders will weigh against the weaker reported quarter.
Q2 2026 revenue was $151.0 million versus $172.9 million in Q2 2025; excluding settlement revenue, revenue rose 3%.
Operating loss was $19.6 million versus operating income of $30.1 million a year earlier; net loss was $17.9 million versus net income of $34.5 million.
2026 revenue guidance raised to $610 million to $630 million from $600 million to $625 million.
Cash and cash equivalents and marketable securities totaled $552.0 million as of June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every 10x Genomics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →